GLP-1 Science
What Is a GLP-1 Receptor Agonist? A Simple Explanation
GLP-1 receptor agonists are drugs that mimic the fullness hormone GLP-1. Ozempic, Wegovy, and Mounjaro are all in this c...
GLP-1 and GIP are both incretin hormones — hormones released by the gut after eating that signal the pancreas to produce insulin. They share a functional overlap but act on different receptors, produce different effects when activated pharmacologically, and their relative importance to weight loss medicine has shifted significantly with the development of tirzepatide.
Understanding the distinction between these two hormones explains why drugs that target both outperform drugs that target only one — and clarifies why the GLP-1 pathway specifically became the foundation for modern obesity pharmacotherapy.
What GLP-1 Is
GLP-1 (glucagon-like peptide-1) is produced by L-cells in the small intestine and colon within minutes of eating. It has a very short natural half-life — approximately two minutes in circulation before degradation by DPP-4 enzymes.
GLP-1 activates GLP-1 receptors in the brain (hypothalamus and brainstem), stomach, pancreas, and liver. The results are:
- Appetite suppression: The hypothalamus receives satiety signals that reduce hunger drive
- Gastric slowing: Food moves from the stomach into the intestine more slowly, extending fullness
- Insulin secretion: Pancreatic beta cells release insulin in response to rising blood glucose
- Glucagon suppression: The liver's glucose release is reduced
It is primarily the brain and stomach effects of GLP-1 that drive weight loss in pharmaceutical GLP-1 agonists. The pancreatic effects manage blood sugar.
What GIP Is
GIP (glucose-dependent insulinotropic polypeptide) is produced by K-cells in the duodenum, earlier in the small intestine than GLP-1. Natural GIP also has a short half-life.
GIP activates GIP receptors in the pancreas, fat tissue, and brain. Its primary traditional role was as an insulin secretagogue — stimulating insulin release after eating. It was long considered less important than GLP-1 for weight loss because its receptors in the hypothalamus are less involved in hunger signalling.
The GIP story became more complicated with tirzepatide. Pharmacological GIP receptor activation, when combined with GLP-1 receptor activation, produces greater weight loss than either alone. The mechanism appears to involve:
- Direct effects on fat cell metabolism (lipolysis)
- Synergistic amplification of GLP-1's hypothalamic effects
- Possible reduction of the nausea produced by GLP-1 agonism alone
Why Combining Both Outperforms Either Alone
Tirzepatide is a dual GIP/GLP-1 receptor agonist and produces 20.9% average weight loss at maximum dose compared to 14.9% for GLP-1-only semaglutide. This 6-percentage-point difference is attributable to the GIP component's additive and synergistic effects.
The reason the combination works better is not fully understood. Current evidence suggests GIP does not merely add to GLP-1 effects linearly — it amplifies them. GIP receptor activation in fat tissue accelerates fat mobilisation during calorie deficit. GIP in the brain may interact with GLP-1 signalling in ways that reset the appetite set-point more aggressively.
Why GLP-1 Became the Primary Target First
GLP-1 agonists were developed first and succeeded first because:
- GLP-1's hypothalamic effects on appetite are direct and well-characterised
- GLP-1 agonist development had a two-decade head start (liraglutide approved 2010)
- Early research on GIP's role in obesity was less clear (in some studies, GIP receptor activation appeared to promote fat storage, which seemed counterproductive — the tirzepatide results overturned this view)
The Implication for GLP-1 Pathway Support
Medications and supplements that target the GLP-1 pathway specifically — including METASLIM GLP-1 sublingual drops — engage the core mechanism that semaglutide uses: hypothalamic appetite suppression, gastric slowing, and insulin response enhancement. The GIP component that gives tirzepatide its additional efficacy would require separate receptor targeting. For Pakistani patients, GLP-1 pathway access through a DRAP-registered option provides the core mechanism that both drugs share.